Custom vaccine shows promise in halting rare blood cancer
NCT ID NCT03631043
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a personalized vaccine made from each patient's own blood and bone marrow. The goal was to help the immune system recognize and kill cancer cells in people with smoldering multiple myeloma, a pre-cancer condition. The study involved 30 adults at high risk and focused on safety and whether the vaccine could be successfully made for each person.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common arthritis drug hold off a rare blood cancer?
- Can keytruda stop smoldering myeloma in its tracks?
- Could a common arthritis drug slow down multiple myeloma?
- Simple lifestyle changes and a common heart drug may improve quality of life for myeloma patients
- New study asks: how do early blood disorders really affect daily life?
- Could a drug combo stop smoldering myeloma in its tracks?